8-K
filed June 1, 2026, 4:30 PM ET
ticker CTXR
CIK 0001506251
other material
confidence high
sentiment positive
materiality 0.50
Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned
Citius Pharmaceuticals, Inc.
- Phase 1 trial of LYMPHIR + pembrolizumab in 25 heavily pre-treated gynecologic cancer patients showed 24% ORR (5 partial responses); median duration of response not reached.
- In endometrial cancer patients previously treated with checkpoint inhibitors, ORR was 33%; one response ongoing >3 years.
- 48% of 21 evaluable patients achieved clinical benefit; median PFS among that group was 20.5 months.
- Safety manageable: only one Gr 3 CLS at highest dose; no new safety signals or Gr 3+ immune-related AEs.
- A Phase 2 expansion study is being planned to further evaluate the combo in gynecologic cancers.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-063531
- form_type
- 8-K
- ticker
- CTXR
- cik
- 0001506251
- company_name
- Citius Pharmaceuticals, Inc.
- filed_at
- 2026-06-01T20:30:19+00:00
- discovered_at
- 2026-06-01T20:33:00.296518+00:00
- generated_at
- 2026-06-01T20:39:39.511162+00:00
- sec_items
- ["8.01", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-063531
- json_url
- https://secwatch.observer/filing/0001213900-26-063531.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-063531.md
- text_url
- https://secwatch.observer/filing/0001213900-26-063531.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GIPR
Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit
GENERATION INCOME PROPERTIES, INC.
June 1, 2026, 5:27 PM ET
other_material
Items 1.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MUX
McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M
McEwen Inc.
June 1, 2026, 5:14 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
EMYB
Embassy Bancorp expands stock repurchase program by additional $5M
Embassy Bancorp, Inc.
June 1, 2026, 4:37 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CTOR
Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer
CITIUS ONCOLOGY, INC.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SYRE
Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030
Spyre Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ORKA
Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030
Oruka Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VIASP
Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends
Via Renewables, Inc.
June 1, 2026, 3:06 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
BUKS
CEO Christopher Reedy discloses ongoing cancer treatment; remains in role
BUTLER NATIONAL CORP
June 1, 2026, 12:41 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.